S
Sarepta Therapeutics, Inc. (SRPT)
NMS – Real vaqt narxi. Valyuta: USD
16.85
+0.83 (5.18%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
16.86
+0.01 (0.04%)
Bozordan keyin: Jun 26, 2026, 7:59 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
16.85
+0.83 (5.18%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
16.86
+0.01 (0.04%)
Bozordan keyin: Jun 26, 2026, 7:59 PM EDT
Sarepta Therapeutics, Inc., tijoriy bosqichdagi biofarmatsevtika kompaniyasi, nodir kasalliklarni davolash uchun RNK-yo'naltirilgan terapevtik vositalarni, siRNA platformasini, gen terapiyasini va boshqa genetik terapevtik usullarni kashf qilish va ishlab chiqishga qaratilgan. Kompaniya Duchenne mushak distrofiyasini davolash uchun EXONDYS 51 ni taqdim etadi, bu Duchenne mushak distrofiyasi bo'lgan bemorlarda distrofin genining ekzon 51 o'tkazib yuborishga mos keladigan tasdiqlangan mutatsiyasiga ega; Duchenne mushak distrofiyasini davolash uchun VYONDYS 53 ni taqdim etadi, bu Duchenne mushak distrofiyasi bo'lgan bemorlarda distrofin genining ekzon 53 o'tkazib yuborishga mos keladigan tasdiqlangan mutatsiyasiga ega; Duchenne mushak distrofiyasini davolash uchun AMONDYS 45 ni taqdim etadi, bu Duchenne mushak distrofiyasi bo'lgan bemorlarda distrofin genining ekzon 45 o'tkazib yuborishga mos keladigan tasdiqlangan mutatsiyasiga ega; va ELEVIDYS, AAV asosidagi gen terapiyasi, Duchenne genining ekzon 8 va/yoki ekzon 9 da har qanday yo'qolishga ega bo'lgan bemorlarda kontrendikatsiyaga ega. Kompaniya shuningdek, LGMD2E ni davolash uchun gen terapiyasi dasturi bo'lgan SRP-9003 ni; 1/2a bosqichli klinik sinovlarda RNKi yordamida DUX4 ni tanlab nishonga olib va pasaytiradigan SRP-1001 ni; va 1/2a bosqichli klinik sinovlarda DMPK genining ekspressiyasini kamaytirish uchun SRP-1003 ni ishlab chiqmoqda. Kompaniya F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; G'arbiy Avstraliya Universiteti; Nationwide Bolalar kasalxonasi; Hansa Biopharma; va Dyuk Universiteti bilan hamkorlik va litsenziyalash shartnomalariga ega. Kompaniya 1980 yilda tashkil etilgan va shtab-kvartirasi Kembrij, Massachusetsda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Diane L. Berry Ph.D. | Executive VP and Chief of Global Policy & Advocacy Officer |
| Dr. Louise R. Rodino-Klapac Ph.D. | President of Research & Development and Technical Operations |
| Mr. Douglas S. Ingram Esq., J.D. | CEO & Director |
| Mr. Ian Michael Estepan | President & COO |
| Mr. Ryan H. Wong | Executive VP & CFO |
| Ms. Alison Nasisi | Executive VP & Chief People Officer |
| Ms. Cristin L. Rothfuss J.D. | Executive VP, General Counsel & Company Secretary |
| Patrick Moss Pharm.D. | Executive VP & Chief Commercial Officer |
| Rachael Potter Ph.D. | Chief Scientific Officer |
| Tamara Thornton | Director of Finance, Treasury & Investor Relations |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-06-04 | S-8 | d158109ds8.htm |
| 2026-06-04 | 8-K | d88936d8k.htm |
| 2026-05-06 | 8-K | srpt-20260506.htm |
| 2026-05-06 | 10-Q | srpt-20260331.htm |
| 2026-04-24 | DEFA14A | srpt_def_a14a_2026.htm |
| 2026-04-24 | DEF 14A | srpt-20260424.htm |
| 2026-04-24 | ARS | srpt_2026_ars.pdf |
| 2026-03-02 | 10-K | srpt-20251231.htm |
| 2026-02-25 | 8-K | srpt-20260225.htm |
| 2026-01-12 | 8-K | srpt-20260112.htm |